Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.75 |
| ▸ | RAF1 | P04049 | 2/20 | 0.75 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | EGFR | P00533 | 1/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.72 |
| ▸ | SRC | P12931 | 2/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | BCR | P11274 | 1/20 | 0.64 |
| ▸ | IGF1R | P08069 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451324 | 0.87 | MAP2K1 (0.90) | MAP2K1RAF1MAPK3MAPK1EGFR | |
| SCHEMBL4462442 | 0.87 | EGFR (0.68) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL4466787 | 0.86 | EGFR (0.78) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL346145 | 0.86 | MAP2K1 (1.00) | MAP2K1RAF1MAPK3MAPK1EGFR | |
| SCHEMBL4447752 | 0.85 | MAP2K1 (0.86) | MAP2K1RAF1MAPK3MAPK1EGFR | |
| SCHEMBL4458635 | 0.85 | SRC (0.76) | MAP2K1EGFRERBB2SRCABL1 | |
| SCHEMBL31748812 | 0.85 | MAP2K1 (0.75) | MAP2K1RAF1MAPK3MAPK1EGFR | |
| SCHEMBL4462099 | 0.84 | EGFR (0.56) | MAP2K1RAF1MAPK3MAPK1EGFR | |
| SCHEMBL6383141 | 0.84 | EGFR (1.00) | MAP2K1RAF1MAPK3MAPK1EGFR | |
| SCHEMBL6381620 | 0.84 | MAP2K1 (0.77) | MAP2K1RAF1MAPK3MAPK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | PFIZER INC | 2004-12-02 | — | — | US | claimed |
| US-7585869-B2 | Substituted heterocylces for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1636195-A1 | QUINAZOLINES AND PYRIDO[3,4-D]PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004106308-A1 | QUINAZOLINES AND PYRIDO [3,4-D] PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | PFIZER INC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNY | MAP2K1 4085/4885RAF1 155/4885MAPK3 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.